Novartis marketing services center lands in Ireland; Pfizer faces delay in tearing down Groton building;

 @FiercePharma: CDC study finds U.S. adults still skipping their meds to save money. Until they qualify for Medicare. Report | Follow @FiercePharma

 @EricPFierce: Fleming Laboratories has two plants in Pradesh, India, which were put on import alert Monday by the FDA. Alert | Follow @EricPFierce

> Novartis ($NVS) picked Dublin, Ireland, for a business services center that will employ 100 people; the operation will handle digital marketing, salesforce training and medical communications in Europe. Report

> Pfizer ($PFE) faces a roadblock in its plans for demolishing a former R&D facility in Groton, CT; the city approved an emergency ordinance establishing a 90-day waiting period. Report

> India's trade minister defended the Supreme Court's decision to deny patent protection to Novartis' cancer drug Gleevec, saying the ruling was "justified under the law." Report

> India pushed back its deadline for adding barcodes to pharma exports, giving the industry an extra year to comply with a new track-and-trace system. Report

> Growth in drug ingredients helped fuel an increase in sales at Arseus to $173 million. Report

Medical Device News

 @FierceMedDev: Blood test reveals more vivid GI cancer gene mutations. More | Follow @FierceMedDev

 @MarkHFierce: The U.K. govt is supporting development of an anti-obesity electronic implant, at Imperial College London. Report | Follow @MarkHFierce

 @DamianFierce: The AP has an excellent roundup of all that's happened with $ISRG over the past month or so. More | Follow @DamianFierce

> Former Abaxis worker settles SEC insider trading case. More

> Biomet's sales soar, losses widen after DePuy buyout. Story

> Bausch + Lomb wins FDA panel nod for eye implant. News

Biotech News

 @FierceBiotech: FDA approved morning-sickness pill, to be marketed as Diclegis. Release | Follow @FierceBiotech

 @JohnCFierce: Bristol-Myers' new R&D chief lays out PhIII game plan. More | Follow @JohnCFierce.

 @RyanMFierce: Elsevier scoops up startup Mendeley in controversial bet on open science. Is it worth it? News | Follow @RyanMFierce

> Lundbeck touts promising head-to-head data on depression drug Brintellix. More

> NEA provides $10M to help fuel next-gen cancer R&D at Cleave. Report

> Gilead quickly asks FDA for blockbuster hep C approval. Story

Pharma Manufacturing News

> China, India have yet to meet EU rule on APIs. More

> More Doxil made through J&J 'alternative manufacturing.' Report

> China drugmaker pulls flu treatment tainted with toxic herbs. Story

> Apotex recalls birth control pills. Article

Biotech Research News

 @EmilyMFierce: Merck developing new class of drugs to target therapy-resistant cancer driven by genetic mutations. Report | Follow @EmilyMFierce

> Common sweetener mannitol improves motor functions in Parkinson's flies. More

> Targeted brain stimulation could treat addiction. Item

> New cancer radiation treatment has no harmful side effects in mice. Article

> Some still skeptical of BRAIN initiative as details remain fuzzy. Story

And Finally... China reported a seventh death from a new form of avian flu and two more cases of infection. Report (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.